Published on 29 Feb 2024 on Simply Wall St. via Yahoo Finance
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported And Analysts Have Been Lifting Their Price...
It's been a good week for Fate Therapeutics, Inc. (NASDAQ:FATE) shareholders, because the company has just released its latest yearly results, and the shares gained 4.5% to US$7.14. The results look positive overall; while revenues of US$64m were in line with analyst predictions, statutory losses were 4.3% smaller than expected, with Fate Therapeutics losing US$1.64 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
See our latest analysis for Fate Therapeutics
